Clovis Oncology, Inc. (NASDAQ: CLVS) reported the first set of data from the Phase 3 ARIEL4 study of Rebraca will take place in an oral presentation today at the Society of Gynecologic Oncology Virtual Annual Meeting on Woman’s Cancer.  T..

Eli Lilly & Co. (NYSE: LLY) said on Friday its cancer treatment Lartruvo, approved on an accelerated basis in 2016, failed to improve patient survival in a long-term study and will no longer be prescribed, driving shares down 3%.The Company said..